Pharvaris
PHVS
35 hedge funds and large institutions have $980M invested in Pharvaris in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 7 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
4.11% more ownership
Funds ownership: 99.72% → 103.83% (+4.1%)
3% less funds holding
Funds holding: 36 → 35 (-1)
14% less capital invested
Capital invested by funds: $1.14B → $980M (-$162M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
+$36.5M |
| 2 |
CC
Commodore Capital
New York
|
+$24.6M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$20M |
| 4 |
DM
Deerfield Management
New York
|
+$6.62M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$16.7M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$16M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$9.86M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.99M |
| 5 |
Millennium Management
New York
|
-$4.46M |
PHVS Hedge Fund Activity: Q1 2024 in Review
35 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q1 2024, worth a combined $980M — down 14% from $1.14B a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PHVS and 6 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 12 added.
The largest buyer was General Atlantic, adding an estimated $36.5M. The largest seller was venBio Partners, cutting an estimated $16.7M.
- 35 institutional investors held Pharvaris (PHVS) as of Q1 2024, down from 36 in Q4 2023.
- Funds reported $980M of Pharvaris stock for Q1 2024, down 14% quarter-over-quarter.
- 6 funds opened new Pharvaris positions in Q1 2024 and 7 closed out, a net change of -1 holder.
- The largest Pharvaris buyer in Q1 2024 was General Atlantic, an estimated $36.5M added.
- The largest Pharvaris seller in Q1 2024 was venBio Partners, an estimated $16.7M sold.
Based on aggregated 13F filings for Q1 2024.